Clinical Trial Highlights - GLP-1 agonists

J Parkinsons Dis. 2020;10(2):355-368. doi: 10.3233/JPD-200002.

Authors

Kevin McFarthing¹, Danielle Larson², Tanya Simuni²

Affiliations

¹ Parkinson's advocate, Oxford, UK.
² Parkinson's Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

No abstract available

MeSH terms

Animals
Clinical Trials as Topic*
Exenatide / pharmacology*
Glucagon-Like Peptide-1 Receptor / agonists*
Humans
Hypoglycemic Agents / pharmacology*
Neuroprotective Agents / pharmacology*
Parkinson Disease / drug therapy*

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Neuroprotective Agents
Exenatide